Medtronic PLC is trading 5.4% up at $82.16, extending its post-earnings rally after reporting its strongest annual revenue growth in a decade.
- The company beat fiscal 2026 expectations and announced a dividend increase, supported by upbeat FY27 organic growth guidance.
- Investors are reacting positively to strategic advancements in cardiovascular and surgical robotics segments, helping the stock outperform a mixed market.